Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mucosis closes €5mm second round

Executive Summary

Infectious disease vaccines developer Mucosis BV raised €5mm ($6.9mm) in what appears to be its second financing to current shareholders BioGeneration Ventures, MedSciences Capital, NV NOM (Investment and Development Agency for the Northern Netherlands), and Utrecht Holdings. Also participating was Changchun BCHT Biotechnology Co., which concurrent with the equity investment got Asian rights to Mucosis’ SynGEM prefusion F respiratory syncytial virus vaccine and Mimopath platform.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies